82 results about "Hepatic toxicity" patented technology

The invention is related to methods of treating hepatic fibrosis using A2B adenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g / L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction.

The present invention relates generally to the method of increasing the oral bioavailability, reducing chemotherapy induced toxicity and side effects, and improving the effectiveness of pharmaceutical agents that are poorly absorbed from the gastrointestinal tract. Specifically, the invention relates to poorly absorbed pharmaceutical drugs and converting them to orotate salts. The orotate salts of the drugs can be dosed at lower doses to provide the efficacy benefits of a higher dose, while reducing the drugs' toxic effects at lower doses. Additionally, the orotate salts of pharmaceutical agents have better clearance and reduce the potential for drug-induced hepatic toxicity. Therefore, an especially useful formulation of the orotate salt of the pharmaceutical agent can provide rapid and consistent action using a lower dose while reducing drug interactions and side-effects.

Embodiments of the present invention provide a drug hepatotoxicity prediction method and device, which relate to the technical field of drug prediction. The method comprises: after acquiring the data of the drug to be tested, classifying the data of the drug to be tested according to a preset classifier group to obtain a plurality of initial classification results; and then based on the plurality of initial classification results and the preset voting strategy According to the rule, a classification result is obtained, and the classification result represents the hepatotoxicity of the drug data to be tested. By classifying the drug data through the preset classifier group and voting strategy, the hepatotoxicity of the drug data can be obtained, the prediction efficiency and accuracy can be improved, and the future development needs of the pharmaceutical industry can be adapted. More effective control of development costs.

The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and / or a medicament for the prevention and / or treatment of elevated blood levels of cholesterol and triglycerides related to steatosis and hepatotoxic effects of medicaments and viral infections. In particular, the invention relates to the use of a sphingolipid such as phytosphingosine, sphingosine, sphinganine, ceramide, glycosylceramide and / or sphingomyelin, or a precursor or a derivative of a sphingolipid, or a pharmaceutically acceptable salt thereof, for the prevention and / or treatment of hepatotoxic effects such as hepatic steatosis, fibrosis and / or cirrhosis.

The invention provides a hepatoxic substance sieving and evaluating method based on cell states labeled by fluorescence, which is a sieving and evaluating method combining a hardware / software system. The images are acquired by a fluorescence inverted microscope and a computer in real time, the biological information is processed and visualized, the liner dynamic range width of the living cell ismeasured by combining FDA dyeing, and then the relevant parameters for evaluating the hepatoxic substances are provided. The method is quick, sensitive and economical, and is used for quickly detecting the influence of the sieved sample on cell quantity, forms, migration, apoptasis and the like under the condition of maintaining cell structure and function integrity, accurately carrying out quantitative analysis on the activity of the cell labeled by the fluorescence specialty and detecting the activity change of the cell under the function of the hepatoxic substances. The method has reasonable design. The provided sieving and evaluating system has complete structure, and can be used for sieving and evaluating the hepatoxic substances.